Abstract: A method for inhibiting infection of SARS-CoV-2 in a subject is provided, comprising administering an effective amount of plant extract, wherein the plant extract comprises an alcohol extract of the herbal of Menispermaceae, wherein the herbal of Menispermaceae is Stephania cepharantha or Stephania tetrandra.

Abstract: The present invention provides the compound represented by Formula 1, and an organic electric element comprising a first electrode, a second electrode, and an organic material layer formed between the first electrode and the second electrode, wherein the organic material layer comprises the compound represented by Formula 1. The driving voltage of an organic electronic device can be lowered, and the luminous efficiency, color purity and life time of an organic electronic device can be improved by comprising the compound represented by Formula 1 in the organic material layer.

Abstract: Drug formulations, methods and their use in treatment of diseases using formulations of pure di-acid salts of tetrandrine family members, especially d-tetrandrine di-hydrochloride, combined with a pharmaceutical diluent or carrier.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: The present invention relates to a novel berbamine derivative of formula I or a pharmaceutically acceptable salt thereof, a process for preparation of the same, a pharmaceutical composition comprising said compound and its use in manufacture of an antitumor medicament.

Abstract: The present invention belongs to the field of natural medicine and pharmaceutical chemistry and specifically relates to novel 7-substituted fangchinoline derivatives of formula (I) and a pharmaceutically acceptable adduct, complex and salt thereof, to a process for the preparation of these compounds, pharmaceutical compositions containing such compounds and their use in preparing antineoplastic medicaments.

Abstract: The present invention belongs to the field of natural medicine and pharmaceutical chemistry and specifically relates to novel 5-substituted tetrandrine derivatives of formula (I) and a pharmaceutically acceptable adduct, complex and salt thereof, to a process for the preparation of these compounds, pharmaceutical compositions containing such compounds and their use in preparing antineoplastic medicaments.

Abstract: Drug formulations, methods and their use in treatment of diseases using formulations of pure di-acid salts of tetrandrine family members, especially d-tetrandrine di-hydrochloride, combined with a pharmaceutical diluent or carrier.

Abstract: The invention relates to novel fluorescent dyes with phosphorylated hydroxymethyl groups, a method for preparing the same as well as to their use in imaging techniques. The fluorescent dyes are coumarin, rhodamine or BODIPY dyes having of one of the following general formulae I-III: wherein W=OP(O) Y1Y2 or P(O) Y1Y2, where Y1 and Y2 independently denote any of the following residues: OH, O(?), ORa and ORb, NHRa and NHRb, NRaRb and NRcRd, ORa and NHRb, ORa and NRbRc, NHRa and NRbRc; and any salt thereof.

Abstract: The invention provides novel berbamine derivatives, and compositions or pharmaceutical compositions thereof. These berbamine derivatives have shown higher potency in killing cancer/tumor cells comparing to berbamine, and can be used in cancer/tumor treatments.

Abstract: Compounds of formulas: are disclosed. The compounds are useful for ameliorating the side effects of therapeutic opiates.

Abstract: This invention pertains generally to processes, uses, methods and materials utilizing particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.

Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.

Abstract: A method for purifying extracted crude d-tetrandrine by dissolving the crude d-tetrandrine powder in ethanol, treating the solution with a decolorizing agent, filtering, reducing the filtered solution under heat and vacuum, cooling the solution, filtering it and drying the filtered cake to yield substantially pure d-tetrandrine.

Abstract: A method for purifying extracted crude d-tetrandrine by dissolving the crude d-tetrandrine powder in ethanol, treating the solution with a decolorizing agent, filtering, reducing the filtered solution under heat and vacuum, cooling the solution, filtering it and drying the filtered cake to yield substantially pure d-tetrandrine.

Abstract: The present invention relates to a novel berbamine derivative of formula I or a pharmaceutically acceptable salt thereof, a process for preparation of the same, a pharmaceutical composition comprising said compound and its use in manufacture of an antitumor medicament.

Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections.

Abstract: A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(?)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(?)-ephedrine from the precipitated salt obtained in step (b).

Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.

Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.

Abstract: A method for purifying extracted crude d-tetrandrine by dissolving the crude d-tetrandrine powder in ethanol, treating the solution with a decolorizing agent, filtering, reducing the filtered solution under heat and vacuum, cooling the solution, filtering it and drying the filtered cake to yield substantially pure d-tetrandrine.

Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.

Abstract: The syntheses of the natural products, avrainvillamide and stephacidin B, are provided. The ?,?-unsaturated nitrone functionality of avrainvillamide and its 3-alkylidene-3H-indole 1-oxide core is shown to covalently and reversibly bond to heteroatom-based nucleophiles. This capability may allow these molecules to bind active site nucleophiles and may provide the basis for designing potent and selective enzyme inhibitors. Both avrainvillamide and its dimer stephacidin B have been reported to exhibit antiproliferative activity, and avrainvillamide has been reported to exhibit antimicrobial activity against multi-drug resistant bacteria. Avrainvillamide has been found to target cytoskeleton-linking membrane protein (CLIMP-63) thereby preventing cells from undergoing mitosis. The invention provides syntheses of these natural products as well as analogs of these natural products and their functional cores.

Abstract: The invention provides novel berbamine derivatives, and compositions or pharmaceutical compositions thereof. These berbamine derivatives have shown higher potency in killing cancer/tumor cells comparing to berbamine, and can be used in cancer/tumor treatments.

Abstract: The present invention relates to agonists of the human bitter-taste receptors hTAS2R46, hTAS2R47 and hTAS2R50 and their role in bitter taste transduction. The invention also relates to methods for identifying molecules that modulate, e.g. suppress, or enhance hTAS2R46, hTAS2R47 and hTAS2R50 bitter taste transduction or bitter taste response.

Abstract: The present invention provides novel, water-soluble, red-emitting fluorescent rhodamine dyes and red-emitting fluorescent energy-transfer dye pairs, as well as labeled conjugates comprising the same and methods for their use. The dyes, energy-transfer dye pairs and labeled conjugates are useful in a variety of aqueous-based applications, particularly in assays involving staining of cells, protein binding, and/or analysis of nucleic acids, such as hybridization assays and nucleic acid sequencing.

Abstract: A therapeutic and/or prophylactic agent for nausea and/or vomiting is provided. A therapeutic and/or prophylactic agent for nausea and/or vomiting, comprising a compound of the Formula (I) or a pharmaceutically acceptable salt or solvate thereof: R1 and R2 are each independently hydrogen or lower alkyl; R3 is hydrogen or lower alkoxycarbonyl; and R4 is hydrogen or lower alkyl; with the proviso that all of R1 to R3 are not simultaneously hydrogen; and R1 and R4 are not simultaneously hydrogen).

Abstract: The present invention relates generally to analgesic compounds having a mu opioid receptor agonist linked to a delta opioid receptor antagonist, and to methods for producing analgesia using such compounds. As compared to opioids such as morphine, these compounds can cause less tolerance, physical dependence, and/or constipation. These compounds are also more potent than morphine and are able to cross the blood brain barrier, thereby allowing for peripheral (e.g., IV) administration.

Abstract: Compounds of formulas: are disclosed. The compounds are useful for ameliorating the side effects of therapeutic opiates.

Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections.

Abstract: Novel energy transfer dyes which can be used with shorter wavelength light sources are provided. These dyes include a donor dye with an absorption maxima at a wavelength between about 250 to 450 nm and an acceptor dye which is capable of absorbing energy emitted from the donor dye. One of the energy transfer dyes has a donor dye which is a member of a class of dyes having a coumarin or pyrene ring structure and an acceptor dye which is capable of absorbing energy emitted from the donor dye, wherein the donor dye has an absorption maxima between about 250 and 450 nm and the acceptor dye has an emission maxima at a wavelength greater than about 500 nm.

Abstract: The invention provides kappa receptor agonists of formula (I) and delta receptor antagonists of formula (II), wherein R1–R6 X and n have any of the meanings given in the specification, as well as compositions comprising them, methods for their use, and synthetic procedures and intermediates useful for their preparation.

Abstract: This invention relates to: an indole derivative or a pharmaceutically acceptable salt thereof represented by formula (I): wherein R1 is, for example, hydrogen or C1-5 alkyl; R2 is, for example, hydrogen or hydroxy; R3 is, for example, hydrogen or hydroxy; —Z— is a crosslinkage having 2 to 5 carbon atoms; m is an integer from 0 to 3; n is an integer from 0 to 10; R4 and R5 are, for example, fluoro or hydroxy; R9 is, for example, hydrogen or C1-5 alkyl; and R10 and R11 are bound to each other to form, for example, —O—; and a pharmaceutical composition comprising the same, particularly a drug acting on &dgr; opioid receptor.

Abstract: Novel compounds which selectively bind to the &dgr;-opioid receptor have been designed. These compounds have greater selectivity, improved water (blood) solubility, and enhanced therapeutic value as analgesics. Because agonists with selectivity for the &dgr;-opioid receptor have shown promise in providing enhanced analgesis without the addictive properties, the compounds of the present invention are better than morphine, naltrindole (NTI), spiroindanyloxymorphone (SIOM), and other known &mgr;-opioid receptor selectors as analgesics.

Abstract: A compound represented by general formula (I) below; 1

Abstract: Compounds of the formula: are provided, which are selective kappa opioid receptor antagonists, wherein R1 is (C1-C5)alkyl, C3-C6(cycloalkyl)alkyl, C5-C7(cycloalkenyl)alkyl, (C6-C12)aryl, (C6-C12)aralkyl, trans(C4-C5)alkenyl, allyl or furan-2-ylalkyl, R2 is H, OH or O2C(C1-C5)alkyl; R3 is H, (C6-C10)aralkyl, (C1-C5)alkyl or (C1-C5)alkylCO; X is O, S or NY, wherein Y is H or (C1-C5) alkyl; R4 is CH2 (methylene) or C═O (carbonyl), R5 is CH2, C═O or C═NH (imino) and R6 is (C1-C4)alkyl or NH(C1-C4)alkyl, optionally substituted by a non-terminal (C1-C2)alkyl group or by N(R7)(R8) wherein R7 and R8 are individually H or (C1-C3)alkyl, with the proviso that one of R4 or R5 is CH2, and the pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a rhodamine dye for recording layer of the high density optical recording disc, which has a chemical structure as shown in (I): 1

Abstract: The invention provides kappa receptor antagonists of formula (I), wherein R1-R6 X and Y have any of the meanings given in the specification, as well as compositions comprising them, and methods for their use.

Abstract: A class of asymmetric monobenzoxanthene compounds useful as fluorescent dyes are disclosed having the structure 1

Abstract: A liquid crystal display has a first substrate plate and a second substrate plate, and a liquid crystal layer disposed between the plates. A polarizing coating, having molecules of one or more organic dyes capable of forming a lyotropic liquid crystalline phase, is formed overlying a selected surface of each plate. Orientation of the polarizing coating is obtained by applying a force to the dye molecules when in the liquid crystal phase and subsequently converting the liquid crystal phase to a solid film.

Abstract: The present invention provides a method for N-deprotecting an opioid compound, a method for N-deprotecting and O-demethylating an opioid compound, a method for O-demethylating an opioid compound, and a method for O-demethylating a nonpeptidic delta agonist compound or an opioid compound having a tertiary amide with no significant reaction at amide groups.

Abstract: A compound comprising a ligand portion which has binding affinity for an opioid receptor, and a therapeutically or diagnostically effective group selected from radionuclide chelating agents, fluorochromes, toxins, drugs, polyboron moieties, proteins, biological response modifiers, chemical moieties capable of binding to other molecules of interest, and radioisotopes selected from therapeutically effective alpha and beta emitters, and diagnostically effective gamma emitters. The compound may be used in a method of treating cancer, and in a method of imaging opioid receptors either inside or outside of the central nervous system.

Abstract: The present invention provides a method for N-deprotecting an opioid compound, a method for N-deprotecting and O-demethylating an opioid compound, a method for O-demethylating an opioid compound, and a method for O-demethylating a nonpeptidic delta agonist compound or an opioid compound having a tertiary amide with no significant reaction at amide groups.

Abstract: A method for obtaining purified bisbenzylisoquinoline alkaloids from the roots of Stephania Tetrandra involves obtaining, from the roots of Stephania Tetrandra, a precipitate comprising tetrandrine, fangchinoline and compounds which constitute impurities, contacting the precipitate with chloroform to form a chloroform solution in which tetrandrine and fangchinoline is dissolved, separating the chloroform solution containing dissolved tetrandrine and fangchinoline from undissolved impurities, removing chloroform from the chloroform solution to obtain a chloroform extract solid having an enriched tetrandrine and fangchinoline content relative to the precipitate, contacting the chloroform extract solid with cool benzene to form a combination comprising undissolved fangchinoline and a benzene solution in which tetrandrine is dissolved, separating the benzene solution from the undissolved fangchinoline from the first solid, removing benzene from the first benzene solution to form a benzene extract which comprises

Abstract: The present invention provides an indolomorphinan derivative or a pharmacologically acceptable acid addition salt thereof, and an agent for curing and preventing cerebral disorders composed of the derivative and salt thereof, which is represented by the following formula (I): ##STR1## [wherein R.sup.1 represents cyclopropylmethyl or the like; R.sup.2 and R.sup.3 each represent hydroxy methoxy, or the like; R.sup.4 represents hydrogen, methyl, benzyl, 3-isothiocyanatopropyl, or the like; and (R.sup.5).sub.m represents hydrogen, substituted benzo, or the like]. The compounds of the present invention have the excellent effect of preventing damage of the cerebral nerve cells.

Abstract: New morphinane derivatives of the formula ##STR1## their pharmaceutically acceptable salts, a process for their preparation and their use in the manufacture of pharmaceutical preparations.

Abstract: The present invention provides dyes of formula I-XXXIV, described in detail below, and dichroic light polarizers based on the dyes. In the dichroic light polarizers of this invention the dye molecules are aggregated into particles oriented in a predetermined direction on a surface of a substrate to enable the dye to polarize light transmitted through the dye. In another embodiment, a dichroic light polarizer includes a molecularly oriented layer of an organic dye on a surface of a substrate. The layer has a non-periodic arrangement of different polarizing elements. Each of the polarizing elements have differing orientations of the polarization vector in the substrate plane and/or differing colors. The dichroic light polarizer may contain one or more additional dye layers and may have a transparent layer intermediate to the dye layer.

Abstract: A method of therapy wherein there is administered to a person in need of such therapy a pharmacologically effective amount of a rupununine having the formula: ##STR1##

Abstract: A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R4 is hydrogen or lower alkyl, R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically acceptably salt, or a solvate thereof is provided.

Abstract: A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R4 is hydrogen or lower alkyl, R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically acceptably acceptable salt, or a solvate thereof is provided.